Home・Listă Acțiuni・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Închisă

SectorSănătate

13.25 3.27

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

12.53

Maxim

13.62

Indicatori cheie
By Trading Economics
Venit	-1.2M -13M
Vânzări	-1.5M 17M
EPS	-0.45
Marjă de profit	-76.292
Angajați	120
EBITDA	-958K -8.6M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+54.44% upside

Dividende
By Acuity
Următoarele câștiguri	7 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-52M 370M
Deschiderea anterioară	9.98
Închiderea anterioară	13.25

Sentimentul știrilor

By Acuity

31%

69%

97 / 340 Clasament în Healthcare

ENANTA PHARMACEUTICALS INC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31 iul. 2026, 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30 iul. 2026, 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29 iul. 2026, 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28 iul. 2026, 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27 iul. 2026, 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24 iul. 2026, 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21 iul. 2026, 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20 iul. 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Comparație

Modificare preț

ENANTA PHARMACEUTICALS INC Așteptări

Obiectiv de preț

By TipRanks

54.44% sus

Prognoză pe 12 luni

Medie 20 USD 54.44%

Maxim 20 USD

Minim 20 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruENANTA PHARMACEUTICALS INC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor ENANTA PHARMACEUTICALS INC - Dist în ultimele 3 luni.

Sentiment

By Acuity

97 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.